+34 620 10 75 37info@nanbiosis.com

News U27

News U27

New Database Provides Valuable Insights into Predicting Sudden Cardiac Death and Atrial Fibrillation

The BSICoS research group (Unit 27 of NANBIOSIS) shared 4 years of heart failure data from 1,000 patients on the Physionet portal for scientific use.

Zaragoza, December 2024. The BSICoS research group (Biomedical Signal Interpretation and Computational Simulation) from the Aragón Institute of Engineering Research (I3A), in whcih the Unit 27 of NANBIOSIS is located, has shared a clinical database containing information from 992 heart failure patients. These patients underwent a 24-hour electrocardiogram (ECG) recording and were monitored over a four-year period. This dataset enables advancements in research on predicting the risk of sudden cardiac death using Holter monitoring data.

The Sudden Cardiac Death in Heart Failure (MUSIC) multicenter study, involving eight hospitals across Spain, was designed to evaluate risk indicators for cardiac mortality and sudden cardiac death in individuals with chronic heart failure.

“[The study serves] to develop prognostic models to predict the risk of sudden death and cardiac death, apply the technologies we had, and seek new markers to improve the identification of high-risk patients for potential defibrillator implantation.”

Alba Martín Yebra, BSICoS research group

The initial goal of the project was “to develop prognostic models to predict the risk of sudden death and cardiac death, apply the technologies we had, and seek new markers to improve the identification of high-risk patients for potential defibrillator implantation,” explains Alba Martín Yebra, a researcher from the BSICoS group.

The MUSIC database includes 24-hour Holter recordings, high-resolution ECG data, and clinical data from blood analysis, echocardiography, chest X-rays, and prescribed medications. The database is available on www.physionet.org, an open-access platform managed by the Massachusetts Institute of Technology (MIT) that hosts databases and open-source software for research purposes.

The work describing this database was presented at the latest edition of the “Computing in Cardiology” scientific conference held in Karlsruhe, Germany, where it garnered significant interest from researchers. “In our research group, working with this data allowed us to develop and validate new biomarkers for predicting sudden cardiac death. That’s why we decided to share it with the scientific community so that other groups can use it to validate and reproduce results in their research lines,” notes Alba Martín. Additionally, it serves as an invaluable testing ground for evaluating algorithms based on deep learning or artificial intelligence.

The MUSIC study has been utilized in various works. According to Alba Martín, the dataset “is a valuable resource for developing and evaluating a wide range of non-invasive prognostic biomarkers derived from the ECG.” One aspect that makes it particularly interesting is the four-year follow-up period, which documents patient evolution after data collection.

Specifically, the BSICoS group has evaluated parameters based on heart rate turbulence, T-wave morphology, and its dependence on heart rate. These parameters were assessed for predicting mortality due to arrhythmias and the progression of heart failure, proving to be powerful risk predictors.

Finally, MUSIC has served as proof of concept for developing new signal processing techniques for atrial fibrillation, an area where the BSICoS group has been a pioneer.

Access to the MUSIC database: https://physionet.org/content/music-sudden-cardiac-death/1.0.0/

Alba Martín, Juan Pablo Martínez, and Pablo Laguna, researchers from the BSICoS group.

This article was written by Melania Bentué – I3A Communications and translated by the NANBIOSIS team.

What is NANBIOSIS?

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

Leading scientists

The main value of NANBIOSIS is our highly qualified and experienced academic scientists, working in public institutions, renowned universities and other research institutes.

Custom solutions

Designed for either scientific collaboration or the private industry, we adapt our services to your needs, filling the gaps and paving the way towards the next breakthrough.

Cutting-Edge facilities

Publicly funded, with the most advanced equipment, offering a wide variety of services from synthesis of nanoparticles and medical devices, including up to preclinical trials.

Standards of quality

Our services have standards of quality required in the pharmaceutical, biotech and medtech sectors, from Good Practices to ISO certifications.

In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024

Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation.

March 8th 2024, NANBIOSIS (Spain)

Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper look.

In these series we delved into the remarkable journeys, research endeavors, and challenges faced by these exceptional women in their pursuit of scientific excellence. From unraveling the mysteries of nanotechnology to pioneering advancements in biosciences, each researcher’s story resonates with perseverance, resilience, and a fervent commitment to breaking barriers. With no doubt their collective message resonates loudly: a call to inspire and empower the next generation of aspiring researchers, regardless of gender, to embark on their own transformative journeys in the world of science and innovation, as well as speaking out on the issues that female researchers still encounter today.

Anna Aviñó speaks about her journey as a researcher and her captivating oligonucleotides.

“Oligonucleotides (…) are recently being approved as new advanced gene therapies for many diseases, including rare and cardiovascular diseases.”

—Dr. Anna Aviñó, scientific coordinator of Unit 29.

Our leading chemist, specialized in nucleic acid chemistry, was the first interview published in these series. She offered us insights into her current projects focused on synthetic and structural studies of oligonucleotides. With a deep understanding of their applications in gene therapies and biosensors, Dr. Aviñó highlighted her contributions to the field and addressed challenges faced as a woman scientist.

Through her expertise and dedication, she advocates for gender equality in science, emphasizing the importance of unbiased education and empowering young women to pursue careers in research.

You can read the full interview here.

Dr. Martín tells us about her innovations in cancer treatment with nanoparticles.

“There are challenging moments during a scientific career (…), but in the end, persistence pays off.”

—Dr. Ana Martín, collaborator scientist in Unit 9.

Ana has a multifaceted background spanning Veterinary Medicine, Biochemistry, and a Ph.D. And in this second part of our series she welcomed us into a world of scientific inquiry and innovation. In this interview, Ana shared her pioneering work in cancer research, utilizing nanoparticles for anti-tumor treatments. Ana also reflected on gender equality in science, the challenges of balancing motherhood with a scientific career, and her aspirations for a more inclusive scientific community.

You can read the full interview here.

Prof. Peña gave us her insightful point of view in overcoming challenges, embracing passion, and cultivating collaborative success towards career estabilization.

“The most important thing in your professional career is to dedicate yourself to something you love (…) that’s incredibly important from a professional point of view.”

—Prof. Estefanía Peña, Scientific Coordinator of Unit 13.

In a captivating interview, Professor Estefanía Peña shared her insights on overcoming challenges, nurturing passion, and fostering collaborative success in achieving career stability. Amidst the bustling R&D environment, Professor Peña’s laboratory serves as a beacon of innovation and determination. With enthusiasm and warmth, she discussed her journey in computational modeling and biomedical engineering, highlighting her experiences, hurdles, and victories. Professor Peña’s story resonates as a testament to perseverance and dedication, offering valuable advice to aspiring researchers on following their passions.

You can read the full interview here.

Our expert in nanocarriers talks about her journey from biotechnology to cancer therapy, an example of passion and perseverance in science.

“I am fortunate to be able to devote myself to something I am passionate about. Research is something I enjoy every day.”

—Dr. María Sancho, Researcher at Unit 9.

Dr. Sancho, our expert in nanocarriers and cancer therapy, shared with us her inspiring journey from biotechnology to groundbreaking research. Set in Zaragoza, Spain, the interview highlighted Maria’s passion and perseverance in pursuing scientific excellence. With warmth and enthusiasm, she discussed her innovative work in developing nanocarriers for targeted drug delivery in cancer treatment. Maria’s story serves as a beacon of inspiration for aspiring scientists, showcasing the transformative power of dedication and curiosity in the pursuit of scientific advancement.

You can read the full interview here.

Dr. Vílchez, our esteemed colloidal chemistry researcher, discusses her focus on water-in-water emulsions and microcoacervates. She highlights gender biases in science and advocates for inclusivity and recognition of women’s contributions.

“I would advise (young women) to pursue their dreams, to show others what they are capable of, and not to let themselves be underestimated.”

—Dr. Susana Vílchez, technical and quality manager of Unit 12.

Dr. Vílchez offered a profound insight into her research endeavors and career trajectory. Specializing in the characterization of colloidal systems such as micelles, vesicles, emulsions, and more, her current focus lies on the intriguing realm of water-in-water emulsions and the formation of microcoacervates, serving as a model for membraneless organelles (MLO) by introducing DNA into these emulsions. During the interview, Dr. Vílchez also shed light on the gender biases prevalent in her field and offered invaluable perspectives on fostering gender equality in science. Through her experiences and unwavering dedication, she inspires young women to pursue their scientific aspirations while advocating for broader inclusivity and recognition of women’s contributions in shaping the scientific landscape.

You can read the full interview here.

Dr. Mincholé discusses cardiac risk assessment, gender challenges in science, and the transformative potential of Digital Twins in healthcare research.

“(I) design and work on a research line that combines computational models with cardiac signals and images. This was done with the aim of stratifying arrhythmic risk and understanding its mechanisms.”

—Dr. Ana Mincholé, researcher at Unit 27.

In this part 6 of our interview series, Dr. Ana Mincholé discussed her groundbreaking work in cardiac risk assessment, gender challenges in science, and the transformative potential of Digital Twins in healthcare research. Dr. Mincholé’s insights offered a glimpse into her innovative approach to integrating computational models with clinical data to advance cardiac care. Her passion for science and dedication to promoting diversity in STEM shine through, underscoring the invaluable contributions of women in the field.

You can read the full interview here.

As a bosus, we have recently published the last of our interviews in our YouTube channel.

In this part VII, we had the pleasure to interview Dr. Eli Prats, a brilliant researches from Unit 8 and a fantastic science communicator. Watch it full here:

About NANBIOSIS:

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

In order to access our Cutting-Edge Biomedical Solutions, place your request here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Women in NANBIOSIS part 6: A conversation with Ana Mincholé on unlocking the heart’s secrets

Dr. Mincholé discusses cardiac risk assessment, gender challenges in science, and the transformative potential of Digital Twins in healthcare research.

This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024 and Woman’s Day 2024. For more interviews, visit our news section here.

March 2024, I3A-Unizar, Zaragoza (Spain)

The meeting room of the High Performance Computing cluster is a comfortable place. A whiteboard full of diagrams occupies a good portion of one of the side walls, creating a welcoming atmosphere where complex concepts become accessible. In stark contrast, a long table is presided over by a large screen and a video call system, making it clear that the boundaries of this place extend beyond its modest size.

The meeting has just ended. It has been intense. In it, the members of NANBIOSIS Unit 27 have given us a comprehensive update on their work. Although our background is more focused on the biomedical aspect, the explanation has been so didactic that we have ended up feeling like part of something much, much larger. Theirs is a work full of versatility and possibilities, only limited by the immense computing power of their machines and the indisputable brilliance of their staff.

Ana Mincholé, one of the team members, waits for the interview to begin. She has already expressed her nervousness to me but, without intending to question her word, I believe she underestimates herself. She was able to open our eyes during that complex meeting, along with the rest of the team, allowing an audience with little computational background to understand the endless possibilities of their equipment. This is a piece of cake for her.

The interview begins.

What motivated you to choose a career in science?

“I’m not sure if science chose me, or if humanities rejected me. I’ve always found physics and mathematics much more entertaining than humanities subjects.”

Interesting… Usually children tend to think that mathematics is very difficult, that physics is very boring… etc.

“It’s a bit strange. I felt more creative solving problems and looking for different ways to solve them, rather than in humanities subjects that I… um (laughs), when I thought I had done something great, they would tell me that… well, that it wasn’t (laughs again). I always knew that I was more into science than humanities disciplines. I liked it more.”

From the beginning, you felt that what they were teaching you in mathematics and physics was more natural for you.

“Yes, the typical problems such as ‘a train leaves from somewhere at such a speed of…’, I found them much more entertaining.”

Could you share with us a little about your research area and the projects you are currently working on?

“In general, my research focuses on the assessment of sudden cardiac death risk in patients with cardiovascular diseases. We work with patients who have suffered heart attacks, cardiomyopathies (heart defects), or patients with bradycardia who need pacemakers. We evaluate the risks using the electrocardiogram, which measures the electrical activity of the heart, and in my case, also through computational models. These are virtual replicas of a patient’s heart that include all their clinical information, and you can evaluate them under different scenarios and see how they respond.”

Does this have to do with the ‘Digital Twins’? That is, replicating on a computer what happens to a person and seeing how the conditions you apply affect them.

“Yes, that’s it. In the case of the heart, for example, we can emulate cardiac anatomy through magnetic resonance images, then you can include fibrotic areas, infarcted areas, electrical dynamics… and with all this, you can simulate the electrical activity of a heart.”

So, not only can you mimic a healthy heart, but also a diseased one.

“That’s right. In hearts, there are always some areas that activate spontaneously. Normally this poses no danger, but in those hearts that already have some arrhythmogenic substrate, meaning that they have some type of previous pathology such as infarcted or fibrotic areas, those activations can cause an arrhythmia.”

What have been the greatest challenges you have faced as a woman in the field of scientific research?

“What a complicated question! There are so many challenges you face simply as a researcher… Perhaps more as a woman? I could highlight that I am a mother of two children, and research is always something that is constantly moving. Facing maternity, personally, I had a lot of plans and I told myself that I wouldn’t leave anything behind. I believed that, as soon as I felt better, I would start doing things, reading articles… but life with a newborn is what it is, and in the end, you don’t do it. And you have that fear and you start to wonder things such as ‘What happened during all this time?’, ‘Will I be able to catch up?’. “

So, I understand that you think the measures that are already in place are insufficient.

“Of course. The thing is research never stops. Science keeps advancing, with or without you. And although in the end it’s not that big of a deal, it’s a feeling you constantly have. Research is a bit strange: on one hand, you have a lot of flexibility, but at the same time, you never really disconnect. Deadlines come, and if you have to work on the weekend, you do it. Or maybe there is that Tuesday in which nothing has come out right, and at night you keep thinking about why the experiment you did in the morning didn’t work out. You keep coming up with ideas, and never really stop thinking about it.”

It is interesting what you’re saying because that applies to a lot of research fields. One might think that in the case of in silico experiments it would not be as bad as, for example, people working with animal models.

“Well, in our field of in silico experiments, you always encounter an error right on Friday before leaving work (laughs). Although during my master’s, I worked on a more experimental project, and it’s true that it’s a whole different level: If something doesn’t work out, you have to wait until it finishes, and I think in that sense, it’s much more demanding.”

Have you experienced any kind of gender bias or added difficulty in your scientific career? How have you addressed this situation?

“I feel like I haven’t faced a significant bias because of being a woman. Also, I’ve felt supported in all the research groups I’ve been part of. It’s true that in some fields, certain attitudes like paternalism and condescension arise because of being young and a woman. But young people stop being young… and women never stop being women (laughs). In those cases, you have to demonstrate that you know what you know, which adds pressure.”

There are fields and careers where there are many more women than men. This is the case for the more ‘bio’ careers. How do you see parity in your field?

“In my field, there’s quite a gender parity. Moreover, in all the groups I’ve worked with, there’s been a fair balance between men and women. I won’t deny that the further you advance in the research career, the more gender bias there is. Generally, there are more men in leadership positions than women, and women tend to have a harder time too. In my case, I haven’t personally experienced any gender bias. I’m lucky to be able to collaborate with people who add value. And with those who don’t, there’s no need for us to collaborate.”

How do you think these barriers can be overcome?

“Visibility. It has worked in other areas. I, being a bit older, remember not long ago when we had a female Minister of Defense, and there were those who were shocked. And nowadays, we don’t give it importance anymore. The visibility of women in science is constantly increasing. An example is the researcher behind the Oxford/Astra Zeneca COVID vaccine, whose presence in the media was quite prominent. We see it more and more often.”

What advice would you give to young women considering a career in science?

“I would tell them to go for it, that it’s a very rewarding career with plenty of opportunities. Sometimes, I think there’s a lack of female role models in science and also in other sectors. This is because even when there’s a mixed team working behind the scenes, the predominant presence of male figures gives a biased picture. And I believe it’s important to convey that science isn’t just for men.”

“(I) design and work on a research line that combines computational models with cardiac signals and images. This was done with the aim of stratifying arrhythmic risk and understanding its mechanisms.

—Dr. Ana Mincholé, researcher at Unit 27.

Have you had any ‘Eureka’ moments in your career? What do you consider to be your greatest achievement or contribution in your field on a professional or personal level?

“Luckily in research, you have quite a few ‘Eureka’ moments. And thank goodness for that! Because there are also many frustrating moments that require a lot of effort and work. Thus when something finally works out, it’s very satisfying. But you have to constantly deal with ups and downs.

As for my greatest achievements, at the end of my PhD, we managed to develop a novel biomarker that was closely related to arrhythmic risk. That was a real high. Something more recent could be to design and work on a research line that combines computational models with cardiac signals and images. This was done with the aim of stratifying arrhythmic risk and understanding its mechanisms. I’m not sure if I would define it as an achievement, but it’s a line of work that I’m particularly proud of.”

Where do you see yourself in 5 or 10 years? And where do you see this technology?

“In the future, I imagine Digital Twins technology being more integrated into clinical practice, with tangible benefits for patients. I think, at the moment, it’s more used at the research level and needs better explanation to understand its potential. But I’m convinced that this technology will be very useful in clinical settings, and I would like to be present when that happens.

Digital Twins of the heart are detailed virtual replicas that incorporate clinical information and specific measurements from each patient in addition to how the heart functions. They are very self-explanatory, and they answer the question of ‘why’ something happens, providing possible explanations for what is going on. Although these models are very descriptive, I don’t see them as incompatible with other types of models, such as artificial intelligence-based solely on data.

In the case of Digital Twins, behaviors and dynamics are introduced, making them much more explanatory. Furthermore, they are multiscale models that cover everything from the cellular level to propagation through cardiac tissue and the torso, even simulating the patient’s electrocardiogram. These multiscale models allow for personalized therapies and specific assessment of arrhythmic risk for each individual.”

How do you think we can encourage more women and girls to participate in science?

“I have participated in initiatives that are fantastic for explaining different professional experiences to people who have to choose a career. I also believe that we need to give visibility to science; not only from the perspective of research, but by showing all the possibilities that pursuing a career in science offers. I think, in the end, one has to choose the career they like the most, and then they can always redirect their decisions to work in what motivates them at each stage of life. The important thing is to decide to do things that fulfill you, motivate you, and do them well.

For example, I studied Physics and never imagined doing a PhD. Then, I went on Erasmus, ended up doing a master’s, and during the master’s thesis project, I discovered that biomedical research fascinated me and fulfilled me. So, I ended up doing a PhD. Life takes you places, and the important thing is to do things that bring you fulfillment and that you enjoy.”

Thank you very much Ana for your time.

“Thanks a lot, to you.”

For more interviews like this, visit our news section here.

Additional information:

The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).

In order to access our Cutting-Edge Biomedical Solutions, place your request here.

NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

Read More

Researchers of two NANBIOSIS units success in the Third Millennium Awards

Researchers of two NANBIOSIS units success in the Third Millennium Awards: the Young Research Talent award to Julia Ramirez (NANBIOSIS U27) and the Research and Future Award to the NFP group (NANBIOSIS U9)

Last November 8, four initiatives received the highest award in the eighth edition of the HERALDO contest Third Millennium Awards which represent the recognition of the Aragonese community from the youngest to the most consolidated trajectories in knowledge transfer, innovation, and scientific dissemination.

The Paraninfo of the University of Zaragoza hosted this event in which researchers CIBER-BBN – NANBIOSIS were recognised this year:

The Films and Nanostructured Particles (NFP) group of INMA and CIBER-BBN, directed by Jesús Santamaría and coordinating NANBIOSIS U9 “Synthesis of Nanoparticles Unit“, was recognised with the Research and Future Award: Manufacturing drugs inside tumors.

Julia Ramírez, from the BSiCoS group of the I3A and CIBER-BBN, coordinator of unit 27 “High Performance Computing Unit” of NANBIOSIS, received the “Young Research Talent” award for her work in the biomedical signal processing.

The Third Millennium Awards’ objective is to recognize the work of people, research centers and groups, institutions and companies in Aragon in three main axes:

Innovation:  Technological Innovation Award

Divulgation:  Best Science and Technology Dissemination Initiative

Research:

– Young Research Talent Awards

– Transfer of Science and University to Business Award

– Research and future award

Julia Ramirez

During her doctorate at Unizar (2017), she developed a methodology to quantify morphological variations in the electrocardiogram (ECG). This quantification led to the T-wave morphology restoration (TMR) index, which was shown to be a stronger predictor of sudden cardiac death than standard clinical indices.

After her doctorate, she moved to work at Queen Mary University of London (QMUL) in London. This was a key point in her research career because she broadened her knowledge in engineering, gaining experience in genetics and bioinformatics. During those years, she obtained two highly competitive European Postdoctoral Fellowships: a WHRI-Academy Cofund (2017) and a Marie Skłodowska-Curie (2018). In recognition of her work, in April 2020, QMUL promoted her to Lecturer in Genetics and Cardiovascular Data Science.

Since January of this year, Julia Ramírez has been back in Zaragoza thanks to a María Zambrano International Talent Attraction Scholarship, giving up the highly competitive Category 2 Talent Attraction of the Community of Madrid, which she had also been awarded. In total, the researcher from Zaragoza has contributed to her field of research with 32 peer-reviewed publications in different disciplines, including bioengineering, cardiology and genetics (13 of her as first author).

In her speech recognized “being in a happy moment”, for being back in Zaragoza, “being away is not always easy” and also for collecting an award for her work that always motivates her to continue forward in a career as the researcher, long and complicated.

The Films and Nanostructured Particles (NFP) group:

«This initiative is the work of many people. It has been a fantastic trip”, said Jesús Santamaría, Principal researcher of the NFP Group

The NFP of the Group was created in 2007 by researchers from different backgrounds, with the aim of concentrating efforts in the development and application of nanostructured materials with an emphasis on nanoparticles, nanoporous interfaces and hybrid systems. Its members have made pioneering developments in the synthesis of nanomaterials and their application in fields ranging from medicine to energy and the environment.

The award recognised the group’s work in the cancer research throughout the project CADENCE (Catalytic Dual-Function Devices Against Cancer), that aims to find a new way to fight this disease, avoiding the problems associated with conventional chemotherapy and its devastating side effects. Three fundamental problems had to be solved. First, developing suitable catalysts (catalytic nanoparticles) capable of operating inside a tumour and manufacturing toxic molecules there. Alternatively, nanoparticles can operate in other ways (by heating remotely) and also produce tumour death. It is also necessary to selectively deliver these catalysts to the tumour, avoiding their accumulation in other organs. Finally, these catalysts must be selectively activated inside the tumour. The answers obtained to each of these problems have opened new paths in the fight against cancer: Catalysts capable of manufacturing toxic substances from within the tumour are used, minimising their diffusion through the body.

This research was funded for five years through an ERC Advanced Grant project endowed with 2.5 million euros. The ERC Advanced Grants are the most prestigious European projects, awarded by the European Research Council in a highly competitive international competition.

Read More

Conversations with women scientists: Cardiology

Esther Pueyo, member of the BSICoS group, which coordinates NANBIOSIS U27 “High Performance Computing” from CIBER-BBN and I3A-UZ, participes with Lina Badimon, professor at the CSIC and group leader at the CIBERCV in the first of a series of videos where two women scientists share their experiences, prepared by the Scientific Culture and Innovation Unit (UCC+i) of the CIBER

Both researchers work in the field of Cardiology and share their passion for science and their vocation to help patients. In this video they talk in depth about their career, their difficulties, their achievements, and what their vision is about the future of women in Science and Cardiology..

“The message to university students is that they can change the future: this is what is known but you can contribute to the knowledge”`, points out Lina Badimon, who is in charge of Women in Cardiology at the European Society of Cardiology. “Women are the majority in the first stages of the scientific career but, then, women do not advance at the speed that men do and this is the point difficult to overcome for women” states Esther Pueyo.

Read More

Women in Signal Processing: Raquel Bailón

The International Day of Women and Girls in Science on February 11 honor women’s significant achievements in science and place a much-needed focus on girls entering Science, Technology, Engineering, and Mathematics (STEM) careers. We want to take this day to congratulate all the women scientists, especially to our scientists at NANBIOSIS ICTS.

In this occasion we want to put the spotlight on Raquel Bailon, researcher of Bsicos Group coordinating NANBIOSIS Unit 27 of High-Performance Computing form CIBER-BBN and University of Zaragoza-I3A, who last month has been highlighted by Inside Signal Processing Newsletter.

In the interview Dr. Raquel Bailon talks about her motivations and aspirations when she was a child and how she chose to develop her career in the field of Signal Processing, explains her passion for biomedical signal processing research and the relevance of her work for society.

Dr. Bailon also gives wise and practical advices to young scientists/engineers in the field of signal processing. Raquel stresses the need of having a deep knowledge of the field of application, working in a multidisciplinary team and promoting collaboration and clinical translation of research, without frontiers

To access the full interview, click here

Read More

Pablo Laguna talking about Physiologically driven biomedical signal processing at the Autonomous University of San Luis Potosí

Zaragoza, October 14th, 2021 Bsicos.i3a.es

Pablo Laguna, Scientific Director of NANBIOSIS U27 High Performance Computing and researcher of BSICoS Group of I3A-UNIZAR and CIBER-BBN gave a talk about Physiologically driven biomedical signal processing at the Faculty of Physics at the Autonomous University of San Luis Potosí (UASLP) in Mexico. He explaned how biomedical signals convey information about biological systems and can emanate from sources of as varied origins as electrical, mechanical or chemical.

In particular, biomedical signals can provide relevant information on the function of the human body. This information, however, may not be apparent in the signal due to measurement noise, presence of signals coming from other interacting subsystems, or simply because it is not visible to the human eye. Signal processing is usually required to extract the relevant information from biomedical signals and convert it into meaningful data that physicians can interpret. In this respect, knowledge of the physiology behind the biomedical measurements under analysis is fundamental. Not considering the underlying physiology may lead, in the best case, to processing methods that do not fully exploit the biomedical signals being analyzed and thus extract only partially their meaningful information and, in the worst case, to processing methods that distort or even remove the information of interest in those signals.

Biomedical Signal Processing (BSP) tools are typically applied on just one particular signal recorded at a unique level of the functional system under investigation and with limited knowledge of the interrelationships with other components of that system. In most instances though, BSP can benefit from an analysis in which more than one signal is evaluated at a time (multi-modal processing), different levels of function are considered (multi-scale processing) and scientific input from different disciplines is incorporated (multi-disciplinary processing). For each problem at hand, the BSP researcher should decide up to which extent information from a number of signals, functional levels or disciplines needs to be incorporated to solve the problem.

As an example, a multi-scale model may be necessary in cases where, for instance, a deeper knowledge of the cell and tissue mechanisms underpinning alterations in a body surface signal is required, whereas a simplified single-scale model may be sufficient in other cases, as when investigating the relationship between two signals measured on the whole human body. At present, there are many biomedical signals that can be acquired and processed using relatively low-cost systems, which makes their use in the clinics very extensive. In particular, non-invasive signals readily accessible to physicians are increasingly being used to improve the diagnosis, treatment and monitoring of a variety of diseases. The presentation aims to illustrate the role played by BSP in the analysis of cardiovascular signals. A set of applications will be presented where BSP contributes to improve our knowledge on atrial and ventricular arrhythmias, the modulation of cardiac activity by the autonomic nervous system (ANS) and the interactions between cardiac and respiratory signals.

Read More

Cristina Pérez, Young Investigator Award at the STAFF congress

Cristina Pérez, has been the winner of the Young Researcher Award (YIA) at the STAFF congress held in Sirolo (Italy), from Septembre 1 to 4, for her work entitled “Characterization of impaired ventricular repolarization by quantification of QT delay after heart rate changes in stress test”

Cristina Pérez is a researcher from BSICoS. Research Group that coordinates NANBIOSIS ICTS Unit 27 “High Performance Computing”, led by PAblo Laguna (from I3A-UNIZAR and CIBER-BBN)

Further information at BSICoS Website

Read More

Diego García, finalist in the Young Researcher Award at the CinC

Researchers from BSICoS Research GroupNANBIOSIS U27 (from I3A-UNIZAR and CIBER-BBN presented their works in the Computing in Cardiology (CinC) Conference, held in Brno (Czech Republic) on 12-15 September.

Diego García was Young Researcher Award (YIA) finalist with the work “Ventilatory Thresholds Estimation Based on ECG-derived Respiratory Rate”.

The purpose of this work is to study the feasibility of estimating the first and second ventilatory thresholds (VT1 and VT2, respectively) by using electrocardiogram (ECG)-derived respiratory rate during exercise testing.

The computation was performed by the ICTS NANBIOSIS, specifically by the High Performance Computing Unit of the CIBER-BBN at the I3A-University of Zaragoza.

Further information at BSICoS Website

Read More

The relevance of biomedical signal processing in the understanding of biological systems

Within the framework of NeoCom2021 Jesús Lázaro, researcher of BSICoS group and NANBIOSIS U27 High Performance Computing form CIBER-BBN and I3A-UZ will explain how biomedical signal processing can be used to improve the current understanding of the functioning of biological systems, conditions related to the cardiovascular, respiratory, and autonomic nervous systems, as well as their interactions.

Prof. Lázaro will review the progress of the WECARMON European Project whose objective is the development of a system for long-term monitoring (months / years) of patients with cardiorespiratory diseases.

NEOCOM: As every year, the Territorial Demarcation of the COIT in Aragon and the Association of Telecommunications Engineers of Aragon collaborate with the Association of Telecommunications Students of the University of Zaragoza (AATUZ) in the organization of the NEOcom conferences that bring ICT companies closer to the university field. All talks are broadcasted on live on the AATUZ YouTube channel (without registration)

Jesús Lázaro and Wecarmon Project

Related news:

NANBIOSIS U27 researchers working in an App for the early diagnosis of covid-19 through mobile phones

Wearable Armband Device for Daily Life Electrocardiogram Monitoring

Read More